TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07605845: Initial Safety and Efficacy, Sequential Group, Adaptive Dose Study of GL-2045 Subcutaneous Injection Repeat Doses in Patients With Immune Thrombocytopenia

Sponsor: Gliknik Inc. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 42 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,507,200

Rescue Site Savings

+$4,950,060

Unlock Full NCT07605845 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07605845 Rescue Dossier →